From the world’s first bovine serum albumin injection, Bosengjian®, to the Miao Beihu® feline trivalent vaccine, which has surpassed 5.5 million doses in total batch releases just 2.5 years after launch, and further to a portfolio of pioneering biologics currently under development, Taizhou Bolaideli Biotechnology Co., Ltd. (hereinafter referred to as Bolaideli) has forged an original‑innovation path—“from zero to one”—for Chinese pet pharmaceutical companies.

The company relocated from Beijing to China Pharmaceutical City in Taizhou, Jiangsu, and within just three years invested over RMB 280 million to build an EU‑compliant pet pharmaceutical industrialization base spanning 31 mu of land with a total floor area of 24,000 square meters.

Ten Years of Steadfast Effort: Solving Global Industry Challenges
Veterinary critical care has long faced an awkward dilemma: in clinical practice across China, veterinarians frequently and illegally use human albumin to treat sick dogs and cats, leading to a disturbingly high incidence of xenoprotein‑induced allergic reactions, anaphylactic shock, and even fatalities. Yet, worldwide, no pharmaceutical company has been willing to invest heavily in developing blood‑protein formulations specifically for pets.

“Overseas industry giants are reluctant to commit substantial capital to the Chinese market over a period of more than a decade,” admitted Dr. Wang Hongwei, founder of Bolaideli. He noted that key constraints include stringent requirements for screening canine plasma raw materials and for disease‑related quarantine standards, extremely high technical barriers in low‑temperature ethanol purification processes, and the prohibitively high costs of clinical trials.

It was precisely this “hard nut to crack” that Bolaideli spent a full ten years tackling.

In 2018, Bosengjian® Canine Albumin Injection officially obtained a Class I New Veterinary Drug Registration Certificate, becoming the world’s first approved blood protein formulation for companion dogs and filling a decades-long international gap in this field. Following its official launch into the market in 2023, the product not only brought an end to the longstanding practice of veterinarians in China illegally using human albumin but also laid the cornerstone for a standardized system of critical care diagnosis and treatment for pets in the country.

In Wang Hongwei’s view, this is merely the starting point for original‑innovation research. The company currently holds nine new veterinary drug registration certificates—comprising one Class I and four Class II—and 18 invention patents, with an additional five to seven new veterinary drug registration certificates expected within the next year.

From Catching Up to Taking the Lead: A Case Study of China’s Vaccine Industry’s Comeback

In the feline trivalent vaccine market, imported products once dominated China for as long as 15 years. After nearly a decade of research, Bolaideli has mastered key core technologies—including the selection of locally prevalent virulent strains, serum-free large-scale cell culture and purification, and precise quantitative detection of the three vaccine‑derived viral antigens—and launched Miaobeihu® feline trivalent vaccine. This product became China’s first feline trivalent vaccine to receive approval for Class II new veterinary drug registration and official production authorization, thereby breaking the market barriers previously held by imported brands.

As of July 2026, Miaobeihu has celebrated its second anniversary on the market, with a total batch release volume reaching 5.5 million doses. It has partnered with over 10,000 pet hospitals and more than 5,000 high-end catteries, firmly maintaining its position as the top-selling domestic feline trivalent vaccine.

“We have gone through three phases: catching up, running alongside, and taking the lead in certain areas,” said Wang Hongwei. He added that Miaobeihu not only boasts product quality far surpassing imported counterparts but also offers more affordable pricing, while having secured seven invention patents, including one U.S. patent. Meanwhile, Bolaideli has concurrently developed a pipeline of therapeutic products—including recombinant protein drugs, monoclonal antibodies, and blood proteins—thereby establishing a comprehensive portfolio spanning “diagnostics + prevention + treatment.”  

Four Major Technology Platforms: Building an “Engine” of Independent Innovation

Underpinning Boli Deli’s high‑density output of innovative drugs are the company’s four foundational technology platforms and four end-to-end industrial chain platforms, which were strategically established a decade in advance.

The company has established three major recombinant protein expression platforms—E. coli, Pichia pastoris, and CHO mammalian cells—tailoring the optimal production strategy to different drug targets to strike a balance between clinical efficacy and industrial-scale profitability. In addition, the company operates a 1,500-square-meter research institute in Beijing and a 4,500-square-meter laboratory complex in Taizhou, equipped with a dual-GCP animal testing platform and a CNAS‑accredited quality‑control facility, thereby forming a dual‑hub structure of “Beijing R&D + Taizhou industrialization.”

“We are not pursuing a copycat strategy; instead, we are building a comprehensive intellectual property system entirely through independent R&D,” said Wang Hongwei, who aligns the company’s strategy with Huawei—committing to self-reliant control over foundational technologies and adopting an end-to-end industrial-chain model, thereby evolving from a pet‑medicine manufacturer into a provider of integrated pet health‑management solutions.

Notably, Bolaideli has obtained GCP accreditation for both biologics and pharmaceuticals—a rare achievement among domestic pet‑pharmaceutical companies. This exclusive qualification reduces clinical trial timelines by more than 30%, enables the concurrent advancement of multiple new‑drug pipelines, and significantly accelerates the registration and approval process for Class I and Class II veterinary medicines.

From Products to Ecosystem: The Broader Vision of an Industry “Game-Changer”

As a vice-presidential member of both the Pet Clinical Medicine Branch of the Chinese Veterinary Medical Association and the Pet Industry Branch of the China Animal Husbandry Association, Bolaideli’s vision extends far beyond simply “selling drugs.”

Since 2015, the company has launched a talent‑support program, establishing public‑interest initiatives such as the Outstanding Young Veterinarian Award and scholarships and teaching‑assistant grants for academic institutions. Over more than a decade, these programs have cumulatively recognized and rewarded over 2,000 young students and practicing veterinarians. In June 2026, the company, in collaboration with the Jinan Small Animal Veterinary Association, pioneered the “Medical Dispute Support Fund,” providing subsidies to cover procedural costs for pet hospitals facing malicious complaints or extortion, thereby encouraging veterinarians to resolve liability issues through formal channels and safeguard their legitimate rights and interests.

“Products are merely the bridge connecting companies and practicing veterinarians; the overall competence of veterinarians will determine the industry’s future ceiling,” said Wang Hongwei.

Regarding industry policy, Wang Hongwei also put forward constructive recommendations: institutionalize the priority review and emergency approval mechanisms, extending the green channel to new veterinary drugs for pet treatment; establish independent technical review standards for the registration of novel veterinary medicines for dogs and cats; and strengthen enforcement and oversight to rigorously crack down on violations such as the indiscriminate use of human medicines and counterfeit drugs in pets.

Charting the Future: China’s Innovative Pet Pharmaceuticals Go Global

In terms of its pipeline, Bolaideli’s strategic positioning is equally noteworthy. Its globally pioneering products—including recombinant feline serum albumin, a monoclonal antibody against feline panleukopenia virus, and recombinant feline erythropoietin—are currently undergoing new veterinary‑drug registration, with approvals expected to be granted sequentially after 2028. The company has also incorporated the pet chronic‑disease segment into its strategic roadmap, advancing the development of therapeutics for age‑related conditions such as renal disease, diabetes, and osteoarticular disorders in a phased manner.

Targeting overseas markets, Bolaideli has established a clear internationalization strategy: leveraging domestically proven products such as Miao Beihu and Boshengjian to form its initial wave of global expansion, while simultaneously pursuing differentiated R&D avenues in areas like IL‑31 and NGF monoclonal antibodies and recombinant blood proteins. For the European and U.S. markets, the company adopts a BD licensing and co‑development model, monetizing its technologies through upfront payments, milestone royalties, and sales‑based revenue shares.

“Let China’s innovative pet medicines become a new, globally accessible, affordable, and trustworthy option for veterinary clinical practice,” said Wang Hongwei.

From a single laboratory to a 24,000-square-meter EU‑standard industrial park, and from a follower once overshadowed by imported products to a global pioneer leading the way, Bolaid’s story of deep cultivation in pet biopharmaceuticals—guided by “focus, expertise, and passion”—mirrors the broader era of transformation in China’s pet pharmaceutical industry, as it leaps from “Made in China” to “Created in China.” (Zhang Weibin, Xu Liang, Han Zhijun)